EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV

Mohammad M Sajadi, Abdolrahim Abbasi, Zahra Rikhtegaran Tehrani, Christine Siska, Rutilio Clark, Woo Chi, Michael S Seaman, Dieter Mielke, Kshitij Wagh, Qingbo Liu, Taylor Jumpa, Randal R Ketchem und 34 weitere

Structure · 2025-07 · 33 (7) · 1150-1164.e8

DOI: 10.1016/j.str.2025.04.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Structure, 2025-07. Verfasst von Mohammad M Sajadi und 45 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Vaccine Research and Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, …. Hauptthemen laut MEDLINE: HIV Antibodies, Antibodies, Neutralizing, Protein Engineering, HIV-1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, Gates Foundation, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential to prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials with "first-generation" bnAbs used alone or in combination show promising antiviral effects but also highlight that additional engineering of "enhanced" antibodies will be required for optimal clinical utility, while preserving or enhancing Current Good Manufacturing Practices (cGMP) manufacturing capability. Here, we report the engineering of an anti-CD4-binding site (CD4bs) bnAb, N49P9.3. Through a series of rational modifications, we produced a variant, N49P9.6-FR-LS, that demonstrates enhanced potency, superior antiviral activity in combination with other bnAbs, low polyreactivity, and longer circulating half-life. Additional engineering for manufacturing produced a final variant, eN49P9, with properties conducive to cGMP production. Overall, these efforts demonstrate the feasibility of developing enhanced anti-CD4bs bnAbs with greatly improved antiviral properties as well as potential translational value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV AntibodiesAntibodies, NeutralizingProtein EngineeringHIV-1HumansHIV InfectionsCD4 AntigensAnimalsBroadly Neutralizing Antibodies

Stichwörter der Autor:innen

ADCCCD4 binding siteHIVHIV curebnAbcombination therapieselite neutralizerengineeringmonoclonal antibodyneutralization

Substanzen

HIV AntibodiesAntibodies, NeutralizingCD4 AntigensBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Divisions of Vaccine Research and Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Medicine, Maryland VA Healthcare System, Baltimore,…
  • Divisions of Vaccine Research and Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Just-Evotec Biologics, 401 Terry Avenue North, Seattle, WA, USA.
  • Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
  • Duke Human Vaccine Institute, Durham, NC, USA.
  • Key Laboratory of Developmental Genes and Human Disease, School of Life Science and Technology, Southeast University, Nanjing, China.

Förderung

  • BLRD VA
  • Gates Foundation
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • National Institute of Standards and Technology
  • National Institute of Allergy and Infectious Diseases
  • US Department of Veterans Affairs
  • National Institute of Allergy and Infectious Diseases Division of Intramural Research

Zitieren

APA

Sajadi, M. M., Abbasi, A., Tehrani, Z. R., Siska, C., Clark, R., Chi, W., Seaman, M. S., Mielke, D., Wagh, K., Liu, Q., Jumpa, T., Ketchem, R. R., Nguyen, D. N., Tolbert, W. D., Pierce, B. G., Atkinson, B., Deming, D., Sprague, M., Asakawa, A., …, & DeVico, A. (2025). A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV. Structure, 33(7), 1150-1164.e8. https://doi.org/10.1016/j.str.2025.04.016

Vancouver

Sajadi MM, Abbasi A, Tehrani ZR, Siska C, Clark R, Chi W, et al. A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV. Structure. 2025;33(7):1150-1164.e8. doi:10.1016/j.str.2025.04.016

BibTeX
@article{Sajadi2025,
  author = {Sajadi, Mohammad M and Abbasi, Abdolrahim and Tehrani, Zahra Rikhtegaran and Siska, Christine and Clark, Rutilio and Chi, Woo and Seaman, Michael S and Mielke, Dieter and Wagh, Kshitij and Liu, Qingbo and Jumpa, Taylor and Ketchem, Randal R and Nguyen, Dung N and Tolbert, William D and Pierce, Brian G and Atkinson, Ben and Deming, Derrick and Sprague, Megan and Asakawa, Andrew and Ferrer, David and Dunn, Yasmin and Calvillo, Sarah and Yin, Rui and Guest, Johnathan D and Korber, Bette and Mayer, Bryan T and Sato, Alicia H and Ouyang, Xin and Foulke, Scott and Habibzadeh, Parham and Karimi, Maryam and Aslanabadi, Arash and Hojabri, Mahsa and Saadat, Saman and Zareidoodeji, Roza and Kędzior, Mateusz and Pozharski, Edwin and Heredia, Alonso and Chen, Hegang and Montefiori, David and Ferrari, Guido and Pazgier, Marzena and Lewis, George K and Jardine, Joseph G and Lusso, Paolo and DeVico, Anthony},
  title = {A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV},
  journal = {Structure},
  year = {2025},
  volume = {33},
  number = {7},
  pages = {1150--1164.e8},
  doi = {10.1016/j.str.2025.04.016}
}
Kostenlos starten →